Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Experts are expecting strong growth driven by the robust sales of Lilly's blockbuster treatments, particularly recent launches. However, there ar